Abstract
The application of gene-therapy strategies for the treatment of cancer has finally been realised in the form of numerous phase I clinical trials. Genetic prodrug activation therapy (GPAT) (figure) uses the transcriptional differences between normal and neoplastic cells to drive the selective expression of a metabolic suicide gene (usually derived from bacteria or viruses) able to convert a non-toxic prodrug to its toxic anabolite.1
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
